Abstract:Seho Kweon, 1, 2 Seong Jin Park, 3 Ha Kyeong Lee, 1 Seo Hee Kang, 4 Kwan-Young Chang, 4 Jeong Uk Choi, 5 Jooho Park, 6 Jung-Hyun Shim, 7 Jin Woo Park, 7 Youngro Byun 1, 3 1 Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, 08826, Republic of Korea; 2 College of Pharmacy, Chonnam National University, Gwangju, 61186, Republic of Korea; 3 College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea; 4 Global R&D Center, IcureBNP, Seoul, 06170, Republic of Korea; 5 College of Pharmacy, Kyung Hee University, Seoul, 02447, Republic of Korea; 6 Department of Biomedical & Health Science, Konkuk University, Chungju, 27478, Republic of Korea; 7 College of Pharmacy and Biomedical and Healthcare Research Institute, Mokpo National University, Jeonnam, 58554, Republic of Korea Correspondence: Jin Woo Park; Youngro Byun, Tel +82 61 450 2704, Email ; Background: For maintenance therapy in type 2 diabetes, glucagon-like peptide-1 agonist (GLP-1A), which exhibits low cardiovascular risk and high efficacy, is a promising peptide therapeutic. However, developing an oral GLP-1A presents challenges due to the analog's poor cellular permeability and gastrointestinal (GI) stability. Methods: To mitigate such limitations, an oral nanoformulation of liraglutide (LG) was designed and achieved by combining LG with bile acid derivatives using the nanoprecipitation method. This strategy allowed the bile acid moieties to localize at the nanoparticle surface, enhancing the binding affinity for apical sodium-dependent bile acid transporter (ASBT) and improving GI stability. The in vitro characteristics, cellular permeability, and absorption mechanisms of the LG nanoformulation (LG/TD-NF) were thoroughly investigated. Furthermore, the in vivo oral absorption in rats and the glucose-lowering effects in a diabetic ( db/db ) mouse model were evaluated. Results: The LG/TD-NF produced neutral nanoparticles with a diameter of 58.7 ± 4.3 nm and a zeta potential of 4.9 ± 0.4 mV. Notably, when exposed to simulated gastric fluid, 65.7 ± 3.6% of the LG/TD-NF remained stable over 120 min, while free LG was fully degraded. Relative to unformulated LG, the Caco-2 cellular permeability of the nanoformulation improved, measuring 10.9 ± 2.1 (× 10 − 6 cm/s). The absorption mechanism prominently featured endocytosis simultaneously mediated by both ASBT and epidermal growth factor receptor (EGFR). The oral bioavailability of the LG/TD-NF was determined to be 3.62% at a dosage of 10 mg/kg, which is 45.3 times greater than that of free LG. In a diabetes model, LG/TD-NF at 10 mg/kg/day exhibited commendable glucose sensitivity and reduced HbA1c levels by 4.13% within 28 days, similar to that of subcutaneously administered LG at a dosage of 0.1 mg/kg/day. Conclusion: The oral LG/TD-NF promotes ASBT/EGFR-mediated transcytosis and assures cellular permeability within the GI tract. This method holds promise for the development of oral GLP-1A peptides as an alternative to injections, potentially enhancing patient adherence to maintenance therapy. Keywords: nanoformulation of GLP-1A, oral liraglutide, ASBT-mediated endocytosis, EGFR Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by inadequate insulin production, and in some instances, a decline in insulin sensitivity as the condition progresses. 1 Orally administered pharmacological agents, such as metformin, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors, are extensively utilized as potential therapeutic interventions for T2DM management in the context of long-term treatment. Moreover, injectable therapeutic peptides, including glucagon-like peptide-1 agonist (GLP-1A) and insulin, often serve as primary treatment modalities. 2,3 Due to their superior glucose-lowering effects and reduced cardiovascular risks compared to chemical-based medications, these therapeutic peptides have garnered significant attention in drug development. Thus, there is an intensified focus on advancing synthesis and purification technologies to further the development of these peptides. 4 However, the need for prolonged and frequent invasive administration can lead to decreased patient compliance and heightened risk for infections, potentially resulting in treatment failure. Several modified forms of GLP-1A have been introduced to mitigate these limitations. Some of these have extended half-lives, such as liraglutide (LG), lixisenatide, albiglu -Abstract Truncated-

832-P: Coadministration of Metformin with GLY-200, a Clinical-Stage Nonabsorbed Drug for the Treatment of Type 2 Diabetes (T2D), Has No Significant Impact on the Oral Absorption of Metformin in the Rat

Gliquidone Versus Metformin: Differential Effects on Aorta in Streptozotocin Induced Diabetic Rats

Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: analysis of results from the CONSENT trial.

Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions

Clinical Pharmacokinetics of Metformin

818-P: Chronic Oral Polymeric Duodenal Exclusion Therapy Has Profound Metabolic Benefits in a T2D Rat Model and Affects Duodenal Morphological Enteroplasticity Similar to RYGB surgery: Implications for T2D Therapy

Lipid Profiling Reveals Different Therapeutic Effects of Metformin and Glipizide in Patients with Type 2 Diabetes and Coronary Artery Disease

Bioequivalence of Related GelShield R Sustained-Release Formulations of Metformin: A Pooled Pharmacokinetic Analysis

Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes

First-in-human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations

Effects of Food and Multiple‐dose Administration on the Pharmacokinetic Properties of HR20033, a Sustained‐release Formulation of Henagliflozin and Metformin for the Treatment of Diabetes, in Healthy Chinese Volunteers

A Drug‐Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2‐ and MATE1‐Mediated Transport of Metformin in Healthy Participants

882-P: Effects of YG1699 and Sotagliflozin on Intestinal Glucose Absorption and GLP-1 in Mice

Coordinated ASBT and EGFR Mechanisms for Optimized Liraglutide Nanoformulation Absorption in the GI Tract

Lack of Drug-Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers

94-LB: A Phase 1, Double-Blind, Placebo-Controlled Multiple Escalating Dose Study of RGT-075 Novel Small-Molecule Oral GLP-1 Receptor Agonist in Adults with Type 2 Diabetes

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects

Differential effects of imeglimin and metformin on insulin and incretin secretion—An exploratory randomized controlled trial

The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial

Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy

GLP-1-Rezeptor-Agonisten bei Metformin-Therapie: Risiko für GI-Nebenwirkungen?